January 13, 2026

Jazz Pharmaceuticals announced a priority review voucher for $200M sale at the annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals announced at the J.P. Morgan Healthcare Conference that they have sold a Priority Review Voucher for $200 Million. This represents a recent high for a PRV sale price. The last time a Voucher sold for over $200 Million was in 2016.

Track every
FDA Priority Review Voucher Program.

Stay updated
Thank you!
Oops! Something went wrong while submitting your email.
HomeHistoryNewsCRL DashboardCNPV DashboardContactPRV Watch Pro
Privacy PolicyTerms and Conditions
Copyright © 2026 PRV Watch

This webpage has been compiled from manually reviewing thousands of documents from the U.S. Securities and Exchange Commission (SEC), U.S. Food and Drug Administrations (FDA), Federal Register, press releases and financial records. The information on this page has been compiled from publicly available sources only and does not include any undisclosed PRV issuance's, transactions or redemptions.

Stay in the loop

News, analysis, and insights from the world of Priority Review Vouchers.

Thank you!
Oops! Something went wrong while submitting your email.